Early data suggest that PD-(L)1 x VEGF bispecifics might challenge Keytruda in triple-negative disease.

So far ASP3082 looks no better than Jiangsu HengRui’s straight KRAS G12D inhibitor.

Patients' expression of CEACAM5 might hold the key to activity after all.

Data suggest a path forward for olomorasib plus Keytruda and chemo in PD-L1 low and negative patients.

The fortunes of RLY-2608 reverse, and a pivotal study will follow.

The group is going beyond EGFR exon 20 insertions, but still has work to do to justify its valuation.

Spectrum’s poziotinib failed in HER2 exon 20 lung cancer, but that isn’t stopping Boehringer and Bayer.

Akeso’s data look impressive, but perhaps not impressive enough to sustain Summit’s valuation.